Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
- 3 April 2024
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (12) , 1521-1526
Abstract
Summary: Background & Aims: The natural progression of hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease (MASLD) is not well‐characterised. We aimed to describe it by conducting a retrospective analysis.Methods: This longitudinal, retrospective analysis of well‐characterised MASLD cohorts followed for hepatic decompensation and death. The sequence of liver‐related events was evaluated, and the median time between hepatic decompensation episodes and death versus. transplantation was measured.Results: Of the 2016 patients identified, 220 (11%) developed at least one episode of hepatic decompensation during a median follow‐up of 3.2 years. Ascites was the most common first liver‐related event [153 (69.5%)], followed by hepatic encephalopathy (HE) [55 (25%)] and variceal haemorrhage (VH) [30 (13.6%)]. Eighteen out of the 220 (8.1%) patients had more than one liver‐related event as their first hepatic decompensation. Among the patients who had the first episode, 87 (39.5%) had a second episode [44 (50.5%) HE, 31 (35.6%) ascites, and 12 (13.7%) VH]. Eighteen out of 220 (8.1%) had a third episode [10 (55.5%) HE, 6 (33.3%) VH, and 2 (11.1%) ascites]. Seventy‐three out of 220 (33.1%) died, and 31 (14%) received liver transplantation. The median time from the first episode to the second was 0.7 years and 1.3 years from the second episode to the third. The median survival time from the first episode to death or transplantation was 2.0 years.Conclusion: The most common first liver‐related event in MASLD patients is ascites. The median survival from the first hepatic decompensation to either death or transplantation is 2 years.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK119460, U01DK061734, U01DK130190, R01DK106419, R01DK121378)
- National Center for Advancing Translational Sciences (5UL1TR001442)
- National Heart, Lung, and Blood Institute (P01HL147835)
This publication has 31 references indexed in Scilit:
- High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort studyHepatology Communications, 2022
- Mechanisms and disease consequences of nonalcoholic fatty liver diseaseCell, 2021
- Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLDHepatology, 2020
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy StudiesClinical Gastroenterology and Hepatology, 2015
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the LiverHepatology, 2014
- Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosisHepatology, 2007